立方制药(003020.SZ)子公司取得一项药品注册证书

Core Viewpoint - The company, Cubic Pharmaceuticals (003020.SZ), has received approval from the National Medical Products Administration for the drug registration certificate of Loxoprofen Sodium Oral Solution, indicating a significant advancement in its product portfolio [1]. Group 1: Company Developments - Cubic Pharmaceuticals' wholly-owned subsidiary, Hefei Chengzhi Biopharmaceutical Co., Ltd. ("Chengzhi Biopharma"), is the entity that received the drug registration certificate [1]. - Loxoprofen Sodium is classified as a non-steroidal anti-inflammatory drug (NSAID) belonging to the phenylpropionic acid class, known for its effective analgesic, anti-inflammatory, and antipyretic properties, particularly its strong analgesic effect [1].